Drugs & Targets Invitae offers no-charge genetic testing to patients with pancreatic cancer September 20, 2019Vol.45 No.35
Drugs & Targets Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma September 13, 2019Vol.45 No.34
Drugs & Targets BioXcel receives Orphan Drug Designation for BXCL701 in AML September 13, 2019Vol.45 No.34
Drugs & Targets Syapse, FDA form research collaboration on the regulatory use of real-world evidence September 06, 2019Vol.45 No.33
Drugs & Targets Calquence granted Breakthrough Therapy designation for CLL September 06, 2019Vol.45 No.33
Drugs & Targets European Commission approves Empliciti + pomalidomide and dexamethasone for multiple myeloma September 06, 2019Vol.45 No.33
Drugs & Targets European Commission approves Imbruvica for expanded use in two indications September 06, 2019Vol.45 No.33
Drugs & Targets FDA Grants XTANDI application Priority Review for metastatic hormone-sensitive prostate cancer September 06, 2019Vol.45 No.33
Drugs & Targets DARZALEX approved for frontline multiple myeloma in Japan September 06, 2019Vol.45 No.33
